تفاصيل مارك
| 000 -LEADER |
|---|
| fixed length control field |
11604namaa22004451i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
EG-GICUC |
| 005 - أخر تعامل مع التسجيلة |
|---|
| control field |
20260427130529.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
260413s2025 ua a|||frm||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloguing agency |
EG-GICUC |
| Language of cataloging |
eng |
| Transcribing agency |
EG-GICUC |
| Modifying agency |
EG-GICUC |
| Description conventions |
rda |
| 041 0# - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
eng |
| Language code of summary or abstract |
eng |
| -- |
ara |
| 049 ## - Acquisition Source |
|---|
| Acquisition Source |
Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
616.994071 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) |
|---|
| Classification number |
616.994071 |
| Edition number |
21 |
| 097 ## - Degree |
|---|
| Degree |
M.Sc |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| Local Call Number |
Cai01.19.02.M.Sc.2025.As.I |
| 100 0# - MAIN ENTRY--PERSONAL NAME |
|---|
| Authority record control number or standard number |
Asmaa Taha Hamed Mohamed Khamis, |
| Preparation |
preparation. |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
In vitro evaluation of the efficacy of manuka honey as anticancer and antiviral complementary agent / |
| Statement of responsibility, etc. |
by Asmaa Taha Hamed Mohamed Khamis ; Supervision Prof. Dr. Samah Aly Loutfy, Prof. Dr. Gang Bao, Dr. Mai Mohamed El-Sayed Lotfy. |
| 246 15 - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
دراسة معملية لتقييم فاعلية عسل المانوكا كعامل تكميلي ونشاطه المضاد للسرطان والفيروسات |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Date of production, publication, distribution, manufacture, or copyright notice |
2025. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
91pages : |
| Other physical details |
illustrations ; |
| Dimensions |
25 cm. + |
| Accompanying material |
CD. |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Source |
rda content |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
Unmediated |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
volume |
| Source |
rdacarrier |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Thesis (M.Sc)-Cairo University, 2025. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Bibliography: pages 73-90. |
| 520 #3 - SUMMARY, ETC. |
|---|
| Summary, etc. |
Background and aim: Breast cancer (BC) is the most frequently diagnosed cancer among women <br/>worldwide and is the second leading cause of cancer-related mortalities. While multiple treatment <br/>options exist, a major challenge remains in achieving effective cancer control while minimizing <br/>adverse effects. Doxorubicin (Dox) is a widely used and highly effective chemotherapy agent for <br/>BC, but its clinical use is limited by significant toxicities, particularly cardiotoxicity, which can lead <br/>to irreversible heart damage and other serious complications. Efforts are still going on to reduce <br/>these toxicities. Given these limitations, there is growing interest in natural compounds with anti-<br/>cancer potential, such as Manuka Honey (MH). MH is valued for its antiproliferative, immune-<br/>modulating properties, and apoptosis-inducing properties, alongside its antibacterial and antiviral <br/>activities. The integration of MH into breast cancer therapy as a complementary agent could offer a <br/>safer, more natural adjunct to conventional treatments. This study aimed to explore how MH can <br/>contribute to a holistic approach in managing cancer and related complications, such as viral <br/>infections, by leveraging its antimicrobial and potentially anti-cancer properties. <br/>Material and Methods: An in-silico analysis was performed to predict the anti-cancer efficacy of <br/>combining Dox with MH by assessing how effectively they interact with key proteins involved in <br/>cell death pathways. Additionally, a computational assessment of their pharmacokinetics was <br/>performed by analyzing Absorption, Distribution, Metabolism, Excretion, and Toxicology <br/>(ADMET) properties. In-vitro experiments involved several approaches: 1) The MTT assay was <br/>used to assess the cytotoxicity of drugs on Vero cells as a normal model and MCF-7 in vitro model; <br/>2) The Wound healing assay was used to study cellular migration; 3) The expression levels of <br/>apoptotic genes ( BAX, Bcl-2, P35, and Caspase-3 proteins). <br/> were also assessed using Quantitative real-time PCR; 4) The DNA content of MCF-7 cells (both <br/>control and those treated with compounds) was evaluated at various stages of the cell cycle. Lastly, <br/>an antiviral assay was conducted to test virucidal and viral adsorption mechanisms against human <br/>Adenovirus type 5 (ADV-5) on Vero cells using real-time PCR. <br/>Results: Docking studies revealed that the novel combination of Dox and methylglyoxal interacts <br/>with its target protein like Dox, suggesting comparable binding affinity and a potential for a similar <br/>mechanism of action. The pharmacokinetics of the two compounds were relatively comparable, <br/>suggesting that they may share a common mechanism. The combined treatment demonstrated a <br/>dose-dependent proliferative inhibitory effect on the tested cells compared to solo treatments, <br/>consistent with doxorubicin’s chemotherapy effect. The CC50 values for MCF-7 BC cells were <br/>determined as follows: 39.5 µg/ml for MH, 7.5 µg/ml for Dox, and significantly lower values when <br/>combining both compounds, 9 µg/ml at a 1:1 MH: Dox ratio and 11.5 µg/ml at a 2:1 ratio. Also, <br/>they exhibited morphological changes after 24 hrs of treatment, which is indicative of apoptosis. <br/>The CC50 of MH on Vero cells was found to be greater than 200 µg/ ml. In contrast, Dox showed <br/>a CC50 of 10.8 µg/ml on normal cells. The combination treatment demonstrated improved safety <br/>profiles: the 1:1 MH: Dox ratio had a CC50 of 71.16 µg/ml, and the 2:1 ratio had a CC50 of 121.50 <br/>µg/ml. The results of the cell migration assay demonstrated that the percentage of gap closure in <br/>cells treated with the combined treatment was relative to that of cells treated with Dox alone after <br/>24hours and 48 hours, which suggests effective inhibition of cell migration. Cell cycle analysis <br/>revealed that cells treated with the combination treatment and Dox alone exhibited increased DNA <br/>content in the G0 phase among MCF-7 cells. In contrast, cells treated with MH alone caused a <br/>significant reduction in S-phase DNA content but led to substantial G1-phase arrest. In the G2-M <br/>phase, the MCF-7 cells treated with MH and the combined treatment exhibited the greatest <br/>decrease in DNA content compared to those treated with Dox only. Further evidence of the <br/>synergistic effect between MH and Dox on apoptosis was observed, as both MH alone and <br/>combination treatments induced apoptosis accompanied by significant upregulation of pro-<br/>apoptotic proteins: Bax, P53, and caspase-3. Concurrently, there was a notable downregulation of <br/>the anti-apoptotic protein BCL-2. Ultimately, MH demonstrated potent antiviral inhibitory effects <br/>against Adenovirus type-5 (ADV-5) by employing mechanisms that prevent viral replication <br/>within cells, including virucidal effects and viral adsorption inhibition. <br/>Conclusion: the combination of Manuka Honey and doxorubicin represents a promising <br/>therapeutic strategy that synergistically enhances anticancer efficacy by inducing apoptosis and <br/>cell cycle arrest, while significantly reducing the inherent toxicity of doxorubicin to normal cells. <br/>Furthermore, the adjunctive antiviral activity of methylglyoxal against ADV-5 offers a potential <br/>added benefit for managing cancer-related complications. These findings advocate for the <br/>integration of natural compounds like methylglyoxal into conventional chemotherapy to improve <br/>selectivity and outcomes, warranting further clinical investigation. |
| 520 #3 - SUMMARY, ETC. |
|---|
| Summary, etc. |
يتميز عسل مانوكا (MH) بخصائص مضادة للأورام والفيروسات، مما يجعله محل اهتمام بالغ لآليات عملهالمحتملة. هدفت هذه الدراسة إلى تقييم تأثير عسل مانوكا بمفرده أو تآزرياً مع عقار الدوكسوربيسين (دوكس) على خلايا سرطان الثدي البشرية MCF-7، واستكشاف إمكاناته في التعامل مع المضاعفات المرتبطة بالسرطان. كشفت النتائج الحاسوبية عن ارتباط قوي لمكونات العسل النشطة بكل من بروتيني كاسباس-3 وBcl-2، مما يشير إلى آلية محتملة للتأثير التآزري بينهما. ولم يغير الدمج بين عسل مانوكا والدوكس بشكل كبير من خصائص ADMET، مما يعزز احتمالية الحفاظ على الفعالية العلاجية مع تقليل السمية غير المستهدفة.<br/>أظهرت النتائج أن الجمع بين عسل مانوكا والدوكس بنسب 1:1 أو 2:1 يعزز التأثير السام للخلايا السرطانية MCF-7 بشكل يماثل تأثير الدوكس وحده. ويُعزى هذا التأثير التآزري إلى تفعيل مسار موت الخلايا المبرمج المعتمد على كاسباس-9، مع ارتفاع ملحوظ في التعبير الجيني للجينات المحفزة للاستماتة في المجموعة المعالجة بالتركيب المشترك. كما كشفت الدراسة أن عسل مانوكا وحده قادر على تحفيز مسارات الاستماتة، حيث سجل تعبير جينات كاسباس-3 وBax مستويات أعلى مقارنة بالعلاج المشترك.<br/>تم تحليل تطور دورة الخلية في خلايا MCF-7 بعد المعالجة بالدوكس أو عسل مانوكا أو كليهما. أظهرت النتائج أن جميع العلاقات الثلاثة تسببت في توقف نمو الخلايا وأوقفت تقدم دورة الخلية بشكل فعال في طور G1، مما يمنع تكاثره.<br/>أدت المعالجة بعسل مانوكا والعلاج المشترك إلى زيادة عدد الخلايا في طور G1، مع انخفاضفي أعداد الخلايا في الأطوار S وG2/M مقارنة بالمعالجة بالدوكسوحدهوهذا يشير إلى أن عسل مانوكا والتركيب المشترك قد يكونان أكثر فعالية في تثبيط تخليق DNA ومنع الخلايا من التقدم نحو الانقسام الخلوي، مما يسهم بشكل مباشر في إيقاف دورة الخلية عند الطور.G1.<br/>تعتبر نقطة تفتيح الطور G1/S لحظة حاسمة في مصير الخلية، حيث يتحدد ما إذا كانت الخلية ستدخل مرحلة الراحة أو تستمر في التكاثر أو تتمايز أو تخضع لموت مبرمج. يؤثر عسل مانوكا على تنظيم الجين p53، مما يؤدي إلى إيقاف دورة الخلية. أظهرت الخلايا المعالجة بالعسل وحده زيادة في التعبير الجيني لـ p54 مصحوباً بتوقف دورة الخلية في الطور G1. وسجل العلاج المشترك أعلى نسبة محتوى DNA في الطور G1.<br/>يمكن أن تسبب العدوى الفيروسية، مثل العدوى بالفيروسات الغدية، مضاعفات خطيرة لمرضى السرطان ذوي المناعة الضعيفة. ونظراً لأن العلاجات التقليدية المضادة للفيروسات ترتبط بمعدلات وفيات مرتفعة، فإن البدائل الطبيعية مثل عسل مانوكا تشكل مجالاً بحثياً واعداً. فقد أظهر العسل خصائص مضادة للفيروسات ومعدلة للمناعة، مما يجعلهخِياراًواعداً في إدارة المضاعفات الفيروسية لدى مرضى السرطان. |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE |
|---|
| Issues CD |
Issues also as CD. |
| 546 ## - LANGUAGE NOTE |
|---|
| Text Language |
Text in English and abstract in Arabic & English. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Cancer cells |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
الخلايا السرطانية |
| 653 #1 - INDEX TERM--UNCONTROLLED |
|---|
| Uncontrolled term |
Manuka honey |
| -- |
Doxorubicin |
| -- |
Breast Cancer |
| -- |
Viral infection |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Samah Aly Loutfy |
| Relator term |
thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Gang Bao |
| Relator term |
thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Mai Mohamed El-Sayed Lotfy |
| Relator term |
thesis advisor. |
| 900 ## - Thesis Information |
|---|
| Grant date |
01-01-2025 |
| Supervisory body |
Samah Aly Loutfy |
| -- |
Gang Bao |
| -- |
Mai Mohamed El-Sayed Lotfy. |
| Universities |
Cairo University |
| Faculties |
National Cancer Institute |
| Department |
Department of Cancer Biology (Virology and Immunology) |
| 905 ## - Cataloger and Reviser Names |
|---|
| Cataloger Name |
Shimaa |
| Reviser Names |
Eman Ghareb |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Dewey Decimal Classification |
| Koha item type |
Thesis |
| Edition |
21 |
| Suppress in OPAC |
No |